文献速递血栓与止血

野生型与R338L-tenase复合物形成的差异是R338L-因子IX检测差异的根源

Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.
PubMed 文献 · Blood Adv · 2023-01-01

本研究通过全球现场研究,在13种一步法凝血试验和2种发色底物试验中表征R338L-FIX表现,产生迄今最大R338L-FIX检测数据集,确认临床FIX:C检测结果差异超过三倍,磷脂和激活试剂均参与一步法差异,发色底物试验产生最 divergent 结果。

要点

  • R338L-FIX活性在不同临床FIX:C检测中差异超过三倍。
  • 磷脂和激活试剂均参与一步法凝血试验的检测差异。
  • 发色底物试验产生的FIX:C结果差异最大。

核心结论

  • R338L-FIX检测差异的规模已明确,相关机制有助于建立基因治疗后R338L-FIX活性测量的最佳实践。

研究设计与样本

  • 全球现场研究,评估R338L-FIX在13种一步法凝血试验和2种发色底物试验中的表现。

主要发现

  • 本研究产生迄今最大的R338L-FIX检测数据集,确认临床FIX:C检测结果差异超过三倍。
  • 磷脂和激活试剂均参与一步法凝血试验的检测差异。
  • 发色底物试验产生最 divergent 的FIX:C结果。
  • 操纵FIX:C发色底物试剂盒表明,R338L-FIX的比活性增益在较低FIX:C浓度时最显著,且在FXa生成早期阶段增强。
  • 在发色底物试验中补充FX可相对R338L-FIX活性减弱FIX-WT活性,提示FX对野生型tenase形成的损害程度大于R338L-FIX tenase。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus (AAV) gene therapy has the potential to functionally cure hemophilia B by restoring factor (F)IX concentrations into the normal range. Next-generation AAV therapies express a naturally occurring gain-of-function FIX variant, FIX-Padua (R338L-FIX), that increases FIX activity (FIX:C) by approximately eightfold compared with wild-type FIX (FIX-WT). Previous studies have shown that R338L-FIX activity varies dramatically across different clinical FIX:C assays, which complicates the monitoring and management of patients. To better understand mechanisms that contribute to R338L-FIX assay discrepancies, we characterized the performance of R338L-FIX in 13 1-stage clotting assays (OSAs) and 2 chromogenic substrate assays (CSAs) in a global field study. This study produced the largest R338L-FIX assay dataset to date and confirmed that clinical FIX:C assay results vary over threefold. Both phospholipid and activating reagents play a role in OSA discrepancies. CSA generated the most divergent FIX:C results. Manipulation of FIX:C CSA kits demonstrated that specific activity gains for R338L-FIX were most profound at lower FIX:C concentrations and that these effects were enhanced during the early phases of FXa generation. Supplementing FX into CSA had the effect of dampening FIX-WT activity relative to R338L-FIX activity, suggesting that FX impairs WT tenase formation to a greater extent than R338L-FIX tenase. Our data describe the scale of R338L-FIX assay discrepancies and provide insights into the causative mechanisms that will help establish best practices for the measurement of R338L-FIX activity in patients after gene therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Foley JH, Shehu E, Riddell A, et al. Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. Blood Adv. 2023. PMID: 35839077. doi:10.1182/bloodadvances.2022007435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。